Expert Opinion on Pharmacotherapy最新文献_第3页

Current perspectives on the pharmacologic treatment of boys and adolescents with congenital hypogonadotropic hypogonadism. 男孩和青少年先天性促性腺功能减退症的药物治疗现状。

IF 3.4 3区医学

Expert Opinion on Pharmacotherapy Pub Date : 2026-09-30 DOI: 10.1080/14656566.2026.2741490

Rodolfo A Rey, Romina P Grinspon

{"title":"Current perspectives on the pharmacologic treatment of boys and adolescents with congenital hypogonadotropic hypogonadism.","authors":"Rodolfo A Rey, Romina P Grinspon","doi":"10.1080/14656566.2026.2741490","DOIUrl":"10.1080/14656566.2026.2741490","url":null,"abstract":"Introduction: Congenital hypogonadotropic hypogonadism (CHH) in boys and adolescents requires age- and developmentally appropriate treatment to address androgen deficiency, testicular maturation, pubertal development, and ultimately fertility. The dynamic physiology of the hypothalamic-pituitary-testicular axis necessitates therapeutic strategies that differ substantially between infancy and adolescence.Areas covered: This review examines current pharmacological approaches to CHH across childhood and adolescence, focusing on testosterone, dihydrotestosterone, gonadotropins, pulsatile gonadotropin-releasing hormone (GnRH), and emerging kisspeptin-based therapies. Literature search was made in Pubmed for the period 1990-2026.Expert opinion: Testosterone remains the standard approach for inducing secondary sexual characteristics and effectively promotes virilization, growth, bone accrual, and psychosocial well-being, but does not induce testicular maturation or spermatogenesis. Gonadotropin therapy, particularly sequential follicle-stimulating hormone followed by luteinizing hormone or human chorionic gonadotropin, more directly promotes Sertoli-cell maturation, testicular growth, and spermatogenesis. Early gonadotropin treatment in infancy can reproduce several features of physiological mini-puberty, although its long-term reproductive benefits remain uncertain. Pulsatile GnRH is physiologically attractive but limited by availability and treatment complexity, whereas kisspeptin remains investigational. Treatment should be individualized according to developmental stage, testicular phenotype, therapeutic goals, anticipated fertility, treatment burden, and patient preferences. Major unmet needs include pediatric-specific formulations, optimized regimens, comparative trials, biomarkers of treatment response, and long-term reproductive outcomes.","PeriodicalId":12184,"journal":{"name":"Expert Opinion on Pharmacotherapy","volume":" ","pages":"1-13"},"PeriodicalIF":3.4,"publicationDate":"2026-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149069317","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Future management of hemophilia A with non-biologic hemostatic agents: a call for precision coagulation. 血友病a的未来管理与非生物止血剂：呼吁精确凝血。

IF 3.4 3区医学

Expert Opinion on Pharmacotherapy Pub Date : 2026-09-24 DOI: 10.1080/14656566.2026.2734120

Johnny N Mahlangu

{"title":"Future management of hemophilia A with non-biologic hemostatic agents: a call for precision coagulation.","authors":"Johnny N Mahlangu","doi":"10.1080/14656566.2026.2734120","DOIUrl":"10.1080/14656566.2026.2734120","url":null,"abstract":"Introduction: The therapeutic landscape of hemophilia A has expanded beyond factor replacement with the emergence of non-biologic pharmacological strategies that modulate endogenous hemostatic pathways. These innovations challenge traditional treatment paradigms and create opportunities for more individualized approaches to hemostatic management.Areas covered: This narrative review examines the evolution of non-biologic pharmacotherapy, focusing on RNA therapeutics, emerging oral small molecules, and future mechanism-based interventions that restore hemostasis by rebalancing coagulation rather than by factor VIII replacement. Literature was identified through searches of PubMed/MEDLINE, Embase, ClinicalTrials.gov, and major hemostasis conference proceedings, and was supplemented by reference screening and screening of regulatory guidance websites. Evidence was critically appraised for scientific quality, mechanistic insight, and clinical relevance. We discuss advances in systems pharmacology, functional biomarkers, combination pharmacology, and implementation science, and introduce Precision Coagulation as a framework for the individualized restoration of hemostatic equilibrium, integrating clinical, laboratory, pharmacodynamic, and biological information.Expert opinion: Non-biologic therapies represent more than new treatment options; they redefine hemophilia pharmacotherapy by establishing hemostatic modulation as a therapeutic principle. Future management will increasingly depend on biomarker-guided, mechanism-based, and patient-centered strategies that integrate biologics, non-biologic therapies, and emerging technologies.","PeriodicalId":12184,"journal":{"name":"Expert Opinion on Pharmacotherapy","volume":" ","pages":"1-22"},"PeriodicalIF":3.4,"publicationDate":"2026-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148955417","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Current and new approaches to the treatment landscape for adults with Waldenström macroglobulinemia. 成人Waldenström巨球蛋白血症的当前和新的治疗方法。

IF 3.4 3区医学

Expert Opinion on Pharmacotherapy Pub Date : 2026-09-22 DOI: 10.1080/14656566.2026.2734125

Camille V Edwards, Jorge J Castillo, Tarek H Mouhieddine, Shayna R Sarosiek

{"title":"Current and new approaches to the treatment landscape for adults with Waldenström macroglobulinemia.","authors":"Camille V Edwards, Jorge J Castillo, Tarek H Mouhieddine, Shayna R Sarosiek","doi":"10.1080/14656566.2026.2734125","DOIUrl":"10.1080/14656566.2026.2734125","url":null,"abstract":"Introduction: Waldenström macroglobulinemia (WM) is an indolent B-cell lymphoma with unique clinical manifestations driven by both tumor infiltration of the bone marrow and extramedullary tissues, as well as IgM-related pathology. Recent therapeutic advances for WM have been largely driven by molecular discoveries, and current agents have significantly improved disease control and progression-free survival. However, WM remains incurable, and novel treatment strategies that balance efficacy with tolerability are needed.Areas covered: This review summarizes current treatment approaches, including chemoimmunotherapy and Bruton tyrosine kinase inhibitors, and discusses emerging therapeutic strategies with a focus on clinical efficacy, toxicity, and evolving treatment paradigms. We also examine the role of combination approaches and novel agents, considering their potential integration into the current treatment landscape.Expert opinion: Despite substantial progress, key challenges remain, including the absence of definitive comparative data between various treatment strategies, the optimal sequencing of available agents, and an understanding of the impact of novel therapies on the depth of hematologic response, as well as long-term clinical and patient-reported outcomes. Future efforts should focus on biologically informed treatment selection and the development of strategies that reduce cumulative toxicities while achieving durable disease control.","PeriodicalId":12184,"journal":{"name":"Expert Opinion on Pharmacotherapy","volume":" ","pages":"1-14"},"PeriodicalIF":3.4,"publicationDate":"2026-09-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148976362","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

New and emerging somatostatin therapies for neuroendocrine tumors: "what is in the pipeline". 新的和新兴的生长抑素治疗神经内分泌肿瘤：“什么是在管道”。

IF 3.4 3区医学

Expert Opinion on Pharmacotherapy Pub Date : 2026-09-21 DOI: 10.1080/14656566.2026.2735443

Lingaku Lee, Tetsuhide Ito, Robert T Jensen

{"title":"New and emerging somatostatin therapies for neuroendocrine tumors: \"what is in the pipeline\".","authors":"Lingaku Lee, Tetsuhide Ito, Robert T Jensen","doi":"10.1080/14656566.2026.2735443","DOIUrl":"10.1080/14656566.2026.2735443","url":null,"abstract":"Introduction: Somatostatin receptors (SSTRs) play a central role in all aspects of management of neuroendocrine/endocrine-neoplasms (NENs). This includes diagnosis, with radiolabeled SSTR ligands localizing the primary/tumor extent, and confirming their NEN nature. Non-radiolabeled-SSTR agonists are first line for controlling the hormone-excess-state for functional NENs (F-NENs) and for initial cytotoxic treatment of advanced tumor-growth. Radiolabeled-SSTR-ligands treat advanced disease. There is increasing need for improvement, because some patients do not respond to SSTA-therapies, others become resistant, in some current imaging with radiolabeled-SSTAs is negative and the ease of ligand use/availability is a problem. Additionally, newer groups of patients are being considered for possible SSTA-treatment with newer SSTA‑related-compounds.Areas covered: In this perspective, the authors briefly review recent advances that are resulting in, or may result in, new/emerging SSTAs that show promise for future use in NEN patients.Expert opinion: This review involves both radiolabeled and non-radiolabeled agents for the future treatment of NENs, strongly supports the conclusion that in the future SSTR‑based-drugs will continue to play prominent roles in all aspects of NEN. Numerous recent studies firmly establish these conclusions, all of which are reviewed here; and they will likely be further supported by additional studies that are in progress and also cited here.","PeriodicalId":12184,"journal":{"name":"Expert Opinion on Pharmacotherapy","volume":" ","pages":"1-25"},"PeriodicalIF":3.4,"publicationDate":"2026-09-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148976405","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Investigating oral blarcamesine for treatment of early Alzheimer's disease. 口服布莱卡梅塞治疗早期阿尔茨海默病的研究。

IF 3.4 3区医学

Expert Opinion on Pharmacotherapy Pub Date : 2026-09-20 DOI: 10.1080/14656566.2026.2732056

Abarajithan Chandrasekaran, Alexandra Paget-Blanc, Boris Decourt, Marwan N Sabbagh

{"title":"Investigating oral blarcamesine for treatment of early Alzheimer's disease.","authors":"Abarajithan Chandrasekaran, Alexandra Paget-Blanc, Boris Decourt, Marwan N Sabbagh","doi":"10.1080/14656566.2026.2732056","DOIUrl":"10.1080/14656566.2026.2732056","url":null,"abstract":"Introduction: Alzheimer's disease (AD) is the most common neurodegenerative dementia, affecting millions globally. Therapies primarily consist of managing symptoms and limiting progression. Further advances in treatment include disease-modifying therapies, many of which have unfavorable safety profiles and provide only modest improvement in cognitive function. The need for novel disease-modifying therapies continues to grow as the burden of AD in the population increases.Areas covered: We outline approved disease-modifying therapies, including autophagy restoration through SIGMAR1 activation and its affect on neuronal homeostasis, and how oral blarcamesine, a SIGMAR1 agonist, demonstrates promise for early‑onset AD management. We then describe the Phase IIa and IIb/III clinical trials supporting the efficacy of blarcamesine in patients with AD and other neurodegenerative diseases. We also discuss recent preclinical evidence supporting a preventive role for blarcamesine in AD. A PubMed search was conducted for relevant literature regarding this topic using keywords including, but not limited to, 'blarcamesine,' 'disease-modifying therapy,' 'precision medicine,' 'sigma-1 receptor,' and 'SIGMAR1 agonist.'Expert opinion: Blarcamesine is a potential oral disease-modifying therapeutic candidate for early-stage AD that acts upstream of amyloid-beta pathogenesis and could prevent AD progression early in the course of AD, with emerging preclinical evidence also supporting its potential for disease prevention.","PeriodicalId":12184,"journal":{"name":"Expert Opinion on Pharmacotherapy","volume":" ","pages":"1-9"},"PeriodicalIF":3.4,"publicationDate":"2026-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148976376","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pharmacological solutions for vitiligo: emerging role of Janus kinase inhibitors. 白癜风的药理学解决方案：Janus激酶抑制剂的新作用。

IF 3.4 3区医学

Expert Opinion on Pharmacotherapy Pub Date : 2026-09-17 DOI: 10.1080/14656566.2026.2730511

Hristina Kocic, Uwe Wollina, Aleksandar Godic, Vesna Karanikolic, Jelena Stojkovic-Filipovic, Masa Golubovic, Yan Valle, Torello Lotti

{"title":"Pharmacological solutions for vitiligo: emerging role of Janus kinase inhibitors.","authors":"Hristina Kocic, Uwe Wollina, Aleksandar Godic, Vesna Karanikolic, Jelena Stojkovic-Filipovic, Masa Golubovic, Yan Valle, Torello Lotti","doi":"10.1080/14656566.2026.2730511","DOIUrl":"10.1080/14656566.2026.2730511","url":null,"abstract":"Introduction: Vitiligo is a chronic autoimmune condition characterized by progressive loss of melanocytes and the development of depigmented skin lesions. Increasing evidence highlights the pivotal role of dysregulated JAK-STAT signaling in disease pathogenesis.Areas covered: A literature search was performed using PubMed/MEDLINE, to identify relevant studies published up to January 2026, about the contribution of JAK-STAT-dependent pathways to vitiligo progression, IFN-γ-induced chemokine production (CXCL9 and CXCL10), recruitment of cytotoxic CD8+ T lymphocytes, and the involvement of tissue-resident memory (T RM) T cells in maintaining localized immune responses. The effects of JAK inhibition across multiple cell populations, including melanocytes, keratinocytes, and immune cells were examined. Current clinical data regarding both topical and systemic JAK inhibitors in the context of targeted repigmentation strategies.Expert opinion: Unlike conventional systemic immunosuppressive therapies, JAK inhibitors enable targeted modulation of specific inflammatory pathways central to vitiligo pathophysiology. Future therapeutic success will likely depend on appropriate patient selection, optimal timing of intervention, and rational combination approaches aimed at sustaining repigmentation and reducing relapse risk. Collectively, these developments support the emerging role of JAK-directed therapy as a significant advancement in the management of vitiligo.","PeriodicalId":12184,"journal":{"name":"Expert Opinion on Pharmacotherapy","volume":" ","pages":"1-16"},"PeriodicalIF":3.4,"publicationDate":"2026-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148905609","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pharmacotherapy of Pythium insidiosum keratitis - a contemporary update. 皮草角膜炎的药物治疗-当代更新。

IF 3.4 3区医学

Expert Opinion on Pharmacotherapy Pub Date : 2026-09-16 DOI: 10.1080/14656566.2026.2734123

Bharat Gurnani, Kirandeep Kaur

{"title":"Pharmacotherapy of Pythium insidiosum keratitis - a contemporary update.","authors":"Bharat Gurnani, Kirandeep Kaur","doi":"10.1080/14656566.2026.2734123","DOIUrl":"10.1080/14656566.2026.2734123","url":null,"abstract":"Introduction: Pythium insidiosum keratitis is an emerging, vision-threatening corneal infection that is increasingly recognized worldwide, particularly in tropical and agrarian regions. Owing to its close clinical resemblance to fungal keratitis, delayed diagnosis and inappropriate antifungal therapy frequently result in rapid stromal destruction, therapeutic keratoplasty, and poor visual outcomes. Unlike true fungi, Pythium insidiosum is an oomycete lacking ergosterol in its cell membrane, rendering conventional antifungal agents largely ineffective and necessitating a paradigm shift toward targeted pharmacotherapy.Areas covered: This review summarizes contemporary advances in the pharmacologic management of Pythium insidiosum keratitis, including mechanisms underlying antifungal resistance, current evidence supporting antibacterial-based therapy such as linezolid and azithromycin, adjunctive anti-collagenolytic and anti-inflammatory approaches, and emerging anti-oomycete therapeutics. Literature from PubMed, Scopus, Embase, and Web of Science was reviewed to evaluate drug susceptibility patterns, translational therapeutic strategies, and evolving precision medicine approaches.Expert opinion: Management of Pythium keratitis is transitioning from empirical antifungal therapy toward targeted anti-oomycete (antibacterial) treatment guided by rapid diagnostics and susceptibility profiling. Future advances will likely integrate molecular diagnostics, AI-assisted therapeutic prediction, nanotechnology-enabled drug delivery, and personalized pharmacologic and surgical strategies to improve globe salvage and visual outcomes.","PeriodicalId":12184,"journal":{"name":"Expert Opinion on Pharmacotherapy","volume":" ","pages":"1-21"},"PeriodicalIF":3.4,"publicationDate":"2026-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148955414","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Evaluating enlicitide decanoate: first oral PCSK9 inhibitor for the treatment of adults with hypercholesterolemia. 评价癸酸烯酸酯：首个口服PCSK9抑制剂治疗成人高胆固醇血症

IF 3.4 3区医学

Expert Opinion on Pharmacotherapy Pub Date : 2026-09-15 DOI: 10.1080/14656566.2026.2732054

Christie M Ballantyne, Angela Pirillo, Alberico L Catapano

{"title":"Evaluating enlicitide decanoate: first oral PCSK9 inhibitor for the treatment of adults with hypercholesterolemia.","authors":"Christie M Ballantyne, Angela Pirillo, Alberico L Catapano","doi":"10.1080/14656566.2026.2732054","DOIUrl":"10.1080/14656566.2026.2732054","url":null,"abstract":"Introduction: Atherosclerotic cardiovascular disease (ASCVD) remains the leading global cause of morbidity and mortality, with elevated low-density lipoprotein cholesterol (LDL-C) as a major modifiable risk factor. Despite intensive statin therapy, many high-risk patients do not achieve increasingly stringent LDL-C goals, highlighting the need for additional lipid-lowering strategies. The development of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors has significantly advanced lipid management, although currently available agents require subcutaneous administration and may be limited by adherence, accessibility, and cost.Areas covered: This review discusses the pharmacological profile, clinical efficacy, safety, and potential therapeutic positioning of enlicitide decanoate, the first oral PCSK9 inhibitor. Evidence from phase 2 and phase 3 CORALreef program clinical trials evaluating enlicitide in patients with hypercholesterolemia, heterozygous familial hypercholesterolemia, and established or high risk for ASCVD is summarized. Available data on enlicitide are also compared with existing lipid-lowering therapies, including statins, ezetimibe, and approved therapies targeting PCSK9.Expert opinion: Enlicitide decanoate is a promising addition to lipid-lowering therapy, potentially expanding access to PCSK9 inhibition through oral administration. However, its definitive clinical role will depend on cardiovascular outcomes data, long-term safety, adherence in real-world practice, and cost-effectiveness compared with established injectable therapies.","PeriodicalId":12184,"journal":{"name":"Expert Opinion on Pharmacotherapy","volume":" ","pages":"1-11"},"PeriodicalIF":3.4,"publicationDate":"2026-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148905658","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Management of erythromelalgia: a narrative review and expert opinion. 红斑性肢痛的治疗：叙述回顾和专家意见。

IF 3.4 3区医学

Expert Opinion on Pharmacotherapy Pub Date : 2026-09-15 DOI: 10.1080/14656566.2026.2734121

Jumana Aldhalaan, Julio C Sartori-Valinotti, Mark Denis P Davis, Paola Sandroni

{"title":"Management of erythromelalgia: a narrative review and expert opinion.","authors":"Jumana Aldhalaan, Julio C Sartori-Valinotti, Mark Denis P Davis, Paola Sandroni","doi":"10.1080/14656566.2026.2734121","DOIUrl":"10.1080/14656566.2026.2734121","url":null,"abstract":"Introduction: Erythromelalgia (EM) is a rare disorder predominantly affecting distal extremities characterized by episodes of painful burning erythema, often precipitated by heat and exercise. Treatment is challenging due to limited evidence and lack of guidelines.Areas covered: This article provides an overview of the available literature on EM, with special emphasis on management strategies including lifestyle modification, nonpharmacologic, pharmacologic, procedural, and rehabilitative interventions. PubMed was searched using the advanced search function with the terms 'erythromelalgia AND therapies AND management' from database inception through 16 April 2026.Expert opinion: Management of EM is challenging as there is no cure. It requires an individualized step wise approach due to its heterogenous presentation and variable treatment responses. The primary goal of treatment is to control symptoms and maintain quality of life. In this article, we outline our treatment approach for management including an initial evaluation for underlying causes or associations and treating them if present. First-line therapies include lifestyle modifications, trigger avoidance, and trial of various topical therapies. If not fully responding to first line therapy, we consider initiation of systemic therapies and pain rehabilitative programs.","PeriodicalId":12184,"journal":{"name":"Expert Opinion on Pharmacotherapy","volume":" ","pages":"1-12"},"PeriodicalIF":3.4,"publicationDate":"2026-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148955409","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Immunosuppressive and immunomodulatory therapies in Sjögren's disease: current landscape and future perspectives. Sjögren疾病的免疫抑制和免疫调节疗法：现状和未来展望。

IF 3.4 3区医学

Expert Opinion on Pharmacotherapy Pub Date : 2026-09-12 DOI: 10.1080/14656566.2026.2734124

Veli Yazisiz

{"title":"Immunosuppressive and immunomodulatory therapies in Sjögren's disease: current landscape and future perspectives.","authors":"Veli Yazisiz","doi":"10.1080/14656566.2026.2734124","DOIUrl":"https://doi.org/10.1080/14656566.2026.2734124","url":null,"abstract":"Introduction: Sjögren's disease (SjD) is a systemic autoimmune disorder primarily affecting exocrine glands alongside heterogeneous organ involvement. Historically managed through symptomatic relief and conventional disease-modifying therapies, recent immunological advances have steadily expanded our understanding of its pathogenesis and therapeutic approaches.Areas covered: A systematic literature review regarding therapeutic agents for SjD treatment was conducted across the PubMed, Web of Science, Embase, and Cochrane Library databases.Expert opinion: Over the past two decades, significant advancements in immunology have profoundly deepened our understanding of SjD pathogenesis. This pathophysiological insight is facilitating a paradigm shift from conventional symptomatic relief toward targeted, phenotype-driven biological interventions. The therapeutic pipeline investigating novel agents - including B-cell depletion therapies, BAFF/APRIL pathway inhibitors, T-cell/B-cell interaction modulators (e.g. CD40-CD40L, CTLA-4), type I interferon blockade, and JAK-STAT inhibitors - is expanding rapidly. CAR-T cell therapy application in refractory SjD patients currently represents an emerging, strictly experimental approach requiring rigorous evaluation of safety and long-term feasibility. Ultimately, identifying the most effective therapeutic agents will likely require discovering and implementing biomarkers tailored to specific biological endotypes.","PeriodicalId":12184,"journal":{"name":"Expert Opinion on Pharmacotherapy","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2026-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148955400","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0